Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages
about
Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosisEvaluation of rifapentine in long-term treatment regimens for tuberculosis in miceActivities of poloxamer CRL-1072 against Mycobacterium avium in macrophage culture and in miceEvaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium aviumDevelopment of rifapentine susceptibility tests for Mycobacterium tuberculosisSusceptibility testing of Mycobacterium avium complex isolatesMycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophagesA multi-scale approach to designing therapeutics for tuberculosisA computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatmentPharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study.Rifapentine: its role in the treatment of tuberculosis.Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects.An update on the use of rifapentine for tuberculosis therapy.Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies.Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosisRifapentine is not more active than rifampin against chronic tuberculosis in guinea pigsDose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosisDrug effects on intracellular mycobacteria determined by mass spectrometric analysis of the Na(+)-to-K+ ratios of individual bacterial organisms.Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro.Optimizing the clinical pharmacology of tuberculosis medications.Rifapentine for the treatment of latent tuberculosis.Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?Intracellular pharmacokinetics of telithromycin, a ketolide antibiotic, in alveolar macrophages.Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
P2860
Q28343546-116F4F7B-AA82-4A40-8411-DE82050713E8Q28343604-2270752E-CC2D-4797-A869-8BAA45396EE9Q28343754-8C32400A-1B3C-4652-9DBB-B2E4A3E2E8F6Q28344872-0F509BE3-CA88-4522-8147-925D146F35ABQ28369160-D393F798-54CE-425E-B498-EA444DDDFB4AQ28369453-966DE069-96C3-4B3A-938C-629FBB0F4422Q28379189-01AF3F92-D4B2-464B-8775-B729A19641F3Q28478716-DB15B7B2-8B50-4FC0-AA73-CB460C9B4673Q28647309-A85DF0FC-78C7-45CC-AEEB-E38040054751Q28649754-590D2D98-1612-443A-8A76-B3A8AFD0F861Q33178187-6F7AE803-A73C-40FC-B6C2-B0D227DBC23FQ33779876-25F698DA-A000-4D43-AAB6-4910679AEE37Q33979162-1384AD90-77B8-4D84-8879-8F2606B1FDFAQ35084363-3F3D2107-A05A-4DF3-A08E-945E3E472C5AQ35127235-26F98F34-2422-425C-8022-F9AFFD7F030AQ35687128-CE186CCD-1D9B-481C-A6DA-B4CAC701D036Q36086369-52CF1406-9CFF-4302-A6A3-A22ACBDB93F7Q36171524-73FF353A-67F6-4ED4-9D58-A40A223DCB8EQ36827956-ED6BDA5C-F02B-401C-AFE2-88AC7A1D809CQ36897388-3C574116-631E-4180-9050-E16DEF6EAAD2Q37346929-07F40949-B2BA-4435-88A4-082EA418ADE9Q37612996-1F1A9A77-F61E-48E1-B9D7-7DFF9B0502DAQ38542159-ADE10E98-EB3E-47F9-98AA-01C51BAF3A47Q38933165-600E185A-2030-46F9-8C3E-1942CA6AFDD4Q40095703-2CBEE178-AC16-4019-9E7B-2F7474341EEDQ42932532-BA5A3975-3F10-4F8F-8480-BA95D43BD019Q43507913-F60B4FF7-C990-4735-88EE-5597F0A65294Q44764112-80182378-9998-4FFB-A372-9746B91C2D33
P2860
Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages
description
1995 nî lūn-bûn
@nan
1995 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Comparison of activities of ri ...... residing in human macrophages
@ast
Comparison of activities of ri ...... residing in human macrophages
@en
Comparison of activities of ri ...... residing in human macrophages
@nl
type
label
Comparison of activities of ri ...... residing in human macrophages
@ast
Comparison of activities of ri ...... residing in human macrophages
@en
Comparison of activities of ri ...... residing in human macrophages
@nl
prefLabel
Comparison of activities of ri ...... residing in human macrophages
@ast
Comparison of activities of ri ...... residing in human macrophages
@en
Comparison of activities of ri ...... residing in human macrophages
@nl
P2093
P2860
P356
P1476
Comparison of activities of ri ...... residing in human macrophages
@en
P2093
P2860
P304
P356
10.1128/AAC.39.9.2073
P407
P577
1995-09-01T00:00:00Z